In the most rudimentary form, high throughput screening process is a highly agile and sophisticated method, dedicated to drug discovery. The method is a highly recommended technique to enable automated testing practices of bulky compounds that are either chemical or biological denoting a biological target. End-use adoption of high throughput screening methods are widely incorporated in the pharmaceutical industry at the backdrop of menacing ailments.

High throughput testing practices is gaining enormous momentum in recent drug discovery endeavors owing to its high potential, effici

In the most rudimentary form, high throughput screening process is a highly agile and sophisticated method, dedicated to drug discovery. The method is a highly recommended technique to enable automated testing practices of bulky compounds that are either chemical or biological denoting a biological target. End-use adoption of high throughput screening methods are widely incorporated in the pharmaceutical industry at the backdrop of menacing ailments.

High throughput testing practices is gaining enormous momentum in recent drug discovery endeavors owing to its high potential, efficiency and cost effectiveness to test and assess bulky molecules such as drugs.

WHO Initiatives towards Novel Drug Discovery Projects Intensifies Reliance on High Throughput Screening Tactics

Onset of novel diseases such as the recent coronavirus outbreak globally is further leveraging massive investments in drug discovery the meet the global pandemic. In this regard, international organizations such as WHO is proposing new programs to kickstart potential drug discovery programs. These ongoing developments to test drugs for the novel virus is paving new growth opportunities in global high throughput screening market. New developments are underway to design and develop high throughput screening mechanism to address the growing coronavirus epidemic.

Corona Virus Pandemic Witnesses Large Scale Reliance on High Throughput Screening for Potential Inhibitors 

Researchers at Penn Medicine are putting in enormous efforts towards inventing new drug for coronavirus using their high throughput screening methodologies.  Further, pharmaceutical behemoths are also offering novel opportunities to test new drug formation pertaining to coronavirus. Biopharmaceutical companies are relying heavily on their high throughput screening platforms to hit significant milestones in drug discovery.

In a recent development, in the wake of COVID 19 drug invention, Israeli Health Authorities have been given high throughput screening platform by Cannabics Pharmaceuticals to pursue novel drug discovery endeavors for corona virus. The development is a two-way project that aims at firstly identifying inhibitors of coronavirus besides operating on a high-end diagnostic platform to identify potential victims and carriers. These developments hint at million-dollar opportunities in global high throughput screening market, dedicated mainly towards drug discovery.

Concerning high throughput screening methodologies for advanced drug discovery initiatives, cell-based assays as essential drug development tools is gaining substantial adoption in recent years for superlative results in high throughput screening practices. With astonishing rise in high throughput screening tests, drug development is increasingly diverting towards 3D cell cultures from conventional 2d models.

2D cell cultures were initially cultured on plate and thus do not display native environment of the cells in vivo. However, 3D cell cultures vividly display cell-cell and cell-matrix equations besides referring to the hypoxic conditions, affecting cell behavior. Several clinical trials pertaining to drug discovery fall flat owing to deficient efficacies, previously present in 2d models. However, with 3D modeling surfacing up, the challenge is significantly addressed, also heightening scope for pipeline success inclusive of disease modelling and novel target validation, thereby contributing substantially towards drug discovery.

Laboratory Automation Remains Crucial for High Throughput Screening in Drug Discovery

High-throughput screening has been in rage over the couple of years and has been a constant centerstage for all high-end technological advances. Backed by robotic automation high throughput screening methods have the potential to screen large scale chemical libraries, besides the capabilities of automated robots in screening large molecular libraries intended for drug discovery. High-throughput screening in drug discovery is thoroughly dependent on laboratory automation. Pharmaceutical and lifesciences verticals are thoroughly dependent on robotic expertise to perform tasks that lie beyond human capabilities. Automation in design and lifescience environments skyrocketed dependence on robotics to ensure development of prosthetics as well as drugs for diverse ailments.

High stakes in drug discovery and concomitant reliance on high throughput screening have dually accelerated demands for robotic automation across laboratories on the back of increased throughput capabilities of robotics that also lends economic viability, keeping productivity quotient high. Additional benefits associated with laboratory automation across high throughput screening in drug discovery are its low maintenance and longer shelf life that make robots indispensable for such core laboratory activities.

Proliferating geriatric population continue to cast tremendous burden on the healthcare industry as they remain grossly vulnerable to diseases owing to poor immunity. This particularly calls for high end robotics in diagnostic and clinical trials for pursuing laboratory innovations favoring high end drug formulation.

Efficient Robotics Expands its Robotic Automation Capabilities with Novel Nano-titer-pipe Screening

Capacity expansion projects across healthcare and pharmaceutical companies as well as relentless strides in high throughput screening have dually propagated large-scale demands for laboratory robotics that effectively maneuver efficient cost management and cost reduction to attain large scale productivity with minimum maintenance.

Biopharmaceutical companies are investing aggressively towards developing new testing mechanisms in the realm of high throughput screening and ultra-high throughput screening parameters to attain commercials breakthrough in drug discovery.

Robotics specialist, Efficient Robotics has recently launched commercial scale fully automated microfluidic high-throughput screening to enable high end optimization of proteins, microbial strains, antibodies and enzymes. Efficient Robotics in this regard has affirmed the full-scale commercialization of nano-titer-pipe screening to render high speed screening of a myriad biomolecules within hours and days as opposed to previous time frame of weeks and months altogether. The development is a crucial milestone in leveraging tremendous growth in global high throughput screening market in the forthcoming years.